Search research articles
Contact Us
Filters
Showing results (291-300 of 330) with videos related to
Page
of 33
Sort By:
Nature Communications
|
September 22, 2021
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
Tanya E Keenan, Jennifer L Guerriero, Romualdo Barroso-Sousa, et al.
BMC Cancer
|
May 19, 2021
Genomic features of rapid versus late relapse in triple negative breast cancer
Yiqing Zhang, Sarah Asad, Zachary Weber, et al.
Nature Medicine
|
May 9, 2025
RANO criteria for response assessment of brain metastases based on amino acid PET imaging
Nathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, et al.
The New England Journal of Medicine
|
December 12, 2019
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K Murthy, Sherene Loi, Alicia Okines, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2020
Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer
Ana C Garrido-Castro, Liam F Spurr, Melissa E Hughes, et al.
Nature Medicine
|
June 9, 2025
Author Correction: RANO criteria for response assessment of brain metastases based on amino acid PET imaging
Nathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, et al.
The Lancet. Oncology
|
September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group
Nancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 5, 2026
Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer
Jorge Gomez Tejeda Zanudo, Busem Binboga Kurt, Allison Frangieh, et al.
JCO Precision Oncology
|
September 14, 2020
Identifying <i>ERBB2</i> Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials
Pedro Exman, Ana C Garrido-Castro, Melissa E Hughes, et al.
Cell Reports. Medicine
|
December 17, 2025
Contrastive learning enhances fairness in pathology artificial intelligence systems
Shih-Yen Lin, Pei-Chen Tsai, Fang-Yi Su, et al.
Page
of 33
Search research articles
Search
Showing results (291-300 of 330) with videos related to
Sort By:
Page
of 33
Nature Communications
|
September 22, 2021
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
Tanya E Keenan, Jennifer L Guerriero, Romualdo Barroso-Sousa, et al.
BMC Cancer
|
May 19, 2021
Genomic features of rapid versus late relapse in triple negative breast cancer
Yiqing Zhang, Sarah Asad, Zachary Weber, et al.
Nature Medicine
|
May 9, 2025
RANO criteria for response assessment of brain metastases based on amino acid PET imaging
Nathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, et al.
The New England Journal of Medicine
|
December 12, 2019
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Rashmi K Murthy, Sherene Loi, Alicia Okines, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2020
Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer
Ana C Garrido-Castro, Liam F Spurr, Melissa E Hughes, et al.
Nature Medicine
|
June 9, 2025
Author Correction: RANO criteria for response assessment of brain metastases based on amino acid PET imaging
Nathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, et al.
The Lancet. Oncology
|
September 3, 2013
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group
Nancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 5, 2026
Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer
Jorge Gomez Tejeda Zanudo, Busem Binboga Kurt, Allison Frangieh, et al.
JCO Precision Oncology
|
September 14, 2020
Identifying <i>ERBB2</i> Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials
Pedro Exman, Ana C Garrido-Castro, Melissa E Hughes, et al.
Cell Reports. Medicine
|
December 17, 2025
Contrastive learning enhances fairness in pathology artificial intelligence systems
Shih-Yen Lin, Pei-Chen Tsai, Fang-Yi Su, et al.
Page
of 33